Hot Deals:
amol minechem 601.00 (0.17 %) anglo french drugs 930.00 (3.33 %) anugraha valve 280.00 (1.82 %) apl metals 40.00 (-2.44 %) apollo fashion 107.00 (1.90 %) archit nuwood 500.00 arkfin investments 50.00 arohan 202.00 (1.00 %) assam carbon 265.00 (1.92 %) avalokiteshvar 242.00 (0.83 %) axles india 610.00 (1.67 %) balmer lawrie 202.00 (1.00 %) bharat hotels 345.00 (1.47 %) bima mandi 235.00 (-2.08 %) bira 555.00 (-0.89 %) boat 1,380.00 (-1.43 %) c & s electric 840.00 (-1.18 %) cable corporation 13.00 (-0.76 %) capgemini 11,900.00 (0.85 %) care health 186.00 (-1.59 %) carrier aircon 545.00 (-0.91 %) cial 326.00 (0.31 %) csk 170.00 (-1.16 %) dalmia refract 260.00 (1.96 %) dfm foods 467.00 dsp merrill lynch 1,000.00 east india pharma 39.00 (-2.50 %) eaton fluid 440.00 (3.53 %) electronica plastic 2,100.00 (-0.99 %) elgi ultra 400.00 elofic 2,100.00 (2.44 %) esl steel 46.00 (1.10 %) fincare business 86.00 (3.61 %) fincare sfbl 205.00 (1.49 %) fino paytech 133.00 (-1.48 %) flipkart india 231,001.00 (0.00 %) frick india 15,600.00 (-0.95 %) gkn driveline 1,325.00 (-0.38 %) godavari bio 71.00 (1.43 %) goodluck defence 235.00 (2.17 %) group pharma 300.00 gynofem healthcare 63.00 (-3.08 %) hazira cargo terminals limited 205.00 (1.49 %) hdb financial 1,120.00 (-0.88 %) hdfc ergo 370.00 (1.70 %) hdfc securities 11,300.00 (-1.74 %) hella india 910.00 (1.11 %) hero fincorp 1,990.00 (-0.50 %) hexaware 700.00 (-2.78 %) hicks 1,450.00 (2.11 %) hira ferro 180.00 (2.86 %) honeywell electrical 6,200.00 (1.64 %) ikf finance 312.00 (0.65 %) incred financial 10.00 (1.01 %) incred holdings 165.00 (-1.79 %) india carbon 1,135.00 (-1.30 %) india exposition 121.00 (0.83 %) indian potash 3,250.00 (1.56 %) indian seamless 175.00 (2.94 %) indo alusys 25.75 (-0.96 %) indofil 1,030.00 (0.49 %) infinite computer 405.00 (1.25 %) inkel 29.00 (-3.33 %) jana small finance bank 75.00 kel 610.00 (-2.40 %) kial 126.00 (-1.56 %) klm axiva 15.75 (1.61 %) kurlon limited 1,255.00 (0.40 %) lava 49.00 (-2.00 %) mahindra rural mrhfl 100.00 manipal housing 74.00 (2.07 %) manjushree technopack 3,050.00 (0.66 %) martin & harris 975.00 (-1.52 %) matrix gas 950.00 (-1.04 %) merino 3,350.00 (1.52 %) minosha 282.00 (0.71 %) mitsubishi heavy 207.00 (-0.48 %) mkcl 410.00 (-2.38 %) mobikwik 595.00 (-0.34 %) mohan meakin 2,150.00 (2.38 %) mohfl 13.60 (-0.73 %) msei 1.15 (-0.86 %) msil 36.00 (2.86 %) nayara energy 595.00 (-0.83 %) nayara energy ncd 315.00 (3.28 %) ncdex 220.00 (-0.90 %) ncl buildtek 310.00 (3.33 %) ncl holdings 92.00 (1.10 %) northern arc 400.00 nsdl 825.00 (1.85 %) nse 5,700.00 (1.79 %) orbis financial 340.00 (0.29 %) oswal minerals 60.10 (-1.48 %) otis 3,700.00 (-0.67 %) oyo 43.50 (-1.14 %) panasonic appliances 262.00 (0.77 %) paymate india 520.00 (-0.95 %) pharmeasy 8.50 (-2.30 %) pharmed limited 480.00 (2.13 %) philips domestic 720.00 (-1.37 %) philips india 910.00 (-1.09 %) pnb metlife 70.00 proyuga adtech 25.00 purity flexpack 20.00 ramaraju surgical 255.00 (-1.92 %) rapido 16,650.00 (0.03 %) rasoi 31,500.00 (0.32 %) reliance gic 505.00 (1.00 %) resins plastics 475.00 (3.26 %) ring plus aqua 530.00 (0.95 %) rrl 1,275.00 (2.00 %) rrp s4e innovation 345.00 (-1.43 %) sab miller 490.00 (2.94 %) sbi amc 2,170.00 (0.93 %) sbi general insurance 620.00 (3.33 %) scottish assam 480.00 (2.13 %) shriram life 261.00 (0.38 %) sigachi laboratories 36.00 (-2.70 %) signify 1,310.00 (-1.50 %) smile microfinance 55.00 (1.85 %) sterlite power 748.00 (-0.27 %) studds 915.00 (-1.08 %) svsml 315.00 (2.94 %) swiggy 355.00 (1.43 %) t stanes 810.00 (1.25 %) tata capital 1,040.00 (-0.95 %) teesta agro 77.00 (-6.21 %) trl krosaki 1,300.00 (1.96 %) urban tots 92.00 (2.22 %) utkarsh coreinvest 310.00 (3.33 %) vadilal dairy 10.00 vikram solar 285.00 (-1.72 %) vivriti capital 1,150.00 (-0.86 %) waree energies 2,150.00 (-0.46 %)
×

Celestial Biolabs Annual Reports, Balance Sheet and Financials

Celestial Biolabs Limited (CELESTIAL) Return Comparision with Primex 40 Index

Periods 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years All Time
Primex-40
Celestial Biolabs Limited

Celestial Biolabs Limited Balance Sheet (In Rs.)

 

Particulars

31-03-2019

31-03-2018

EQUITY AND LIABILITY

 

 

Equity Share Capital

              2,258.63

              2,258.63

Other equity

              7,968.67

              7,971.47

Total equity

            10,227.30

            10,230.10

Non-Current Liabilities

 

 

Borrowings

                781.65

                482.00

Deferred tax liabilities

                140.52

                   -2.65

Current Liabilities

 

 

Dues of creditors other than, micro-enterprises and small enterprises

                    55.79

                    43.36

other financial liabilities

                567.35

                470.00

provisions

                  12.22

                  17.59

income tax liabilities

                148.31

                155.05

Total liabilities

              1,705.84

              1,165.35

TOTAL EQUITY AND LIABILITES

            11,933.14

            11,395.45

ASSETS

 

 

Non-Current Assets

 

 

Property plant and equipment

              1,215.70

              1,284.34

Capital work-in-progress

              2,955.81

              2,955.81

Other intangible assets

              3,935.77

              4,025.55

intangible assets under development

              1,567.81

                488.25

other financial assets

 

                  30.10

Current Assets

              9,675.09

              8,784.05

Inventories

                613.50

                395.77

Trade receivables

              1,563.65

              2,076.91

Cash and cash equivalents

                    5.04

                    0.99

other current assets

                  75.85

                137.74

Total current assets

              2,258.04

              2,611.41

TOTAL ASSETS

            11,933.13

            11,395.45

 Celestial Biolabs Limited Profit & Loss Statement (In Rs.)

 

Particulars

31-03-2019

31-03-2018

Revenue from operations

           4,897.42

         4,281.46

other income

               35.65

               0.04

Total revenue

          4,933.07

         4,281.50

Expenses

 

 

cost of material consumed

               51.40

             10.80

purchase of stock in trade

           3,070.24

         2,490.61

changes in inventories of finished goods, work-in-progress and stock-in-trade

            -251.56

            366.59

employee benefits expenses

             148.19

             63.40

finance costs

             125.05

               2.54

depreciation and amortisation expenses

             944.13

            769.54

other expenses

             705.27

            167.16

total expenses

          4,792.72

         3,870.64

profit before tax for the year

              140.35

            410.86

current tax

 

             78.29

differed tax

            -143.17

             13.06

Total comprehensive income for the years

 

 

earning per equity share of face value

 

 

basic

               -0.01

               1.53

diluted

               -0.01

               1.53

 Celestial Biolabs Limited Consolidated Cash Flow Statement (In Rs.)

 

Particulars

31-03-2019

31-03-2018

CASH FLOW FROM OPERATING ACTIVITY

 

 

Net Profit before Tax

               140.36

                410.86

Depreciation

               944.13

                769.54

interest and financial charges paid

               125.05

                   2.54

differed tax

 

                 13.06

provision for tax

 

                -78.29

Operating Profit before Working Capital Charges

            1,209.54

             1,117.71

(increase)/decrease in inventory

             -217.73

                376.00

(increase)/decrease in trade receivables

               513.26

            -1,251.29

(increase)/decrease in other current assets

                61.90

 

(increase)/decrease in trade payables

                12.43

                   0.98

(increase)/decrease in other financial liabilities

                97.63

 

(increase)/decrease in other current liabilities

                 -5.37

                 12.90

(increase)/decrease in provisions

                 -6.74

                 77.35

Cash generated from operating activities

            1,664.92

                 333.65

CASH FLOW FROM INVESTING ACTIVITIES

 

 

Purchase of fixed assets

                 -0.26

 

intangible assets under development

           -1,079.56

 

product development expenses

             -785.73

               -488.25

Net Cash Flow from Investing Activities

           -1,865.55

               -488.25

CASH FLOW FROM FINANCING ACTIVITIES

 

 

Increase/(Decrease) in borrowings

               299.65

               -300.00

Increase/(Decrease) in other financial assets

                30.10

 

Increase/(Decrease) in unsecured loans

 

                417.00

interest and financial charges paid

             -125.05

                  -2.54

Net Cash Flow/(used) From Financing Activities

               204.70

                 114.46

NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS

                    4.07

                 -40.14

CASH & CASD EQUIVALENTS AT THE BEGINNING OF THE YEAR

                  0.99

                 41.13

CASH & CASH EQUIVALENTS AT THE END OF THE YEAR

                    5.06

                     0.99

 Herbal supplements Industry Overview

 

The need for herbal and natural solutions for a range of health issues has led to a strong growth in the Indian herbal supplements market in recent years. At USD 5.26 billion in 2017, the size of the global market for herbal supplements was projected to increase at a compound annual growth rate (CAGR) of 6.2% over the forecast period. A few of the major drivers driving the market expansion include the growing popularity of natural products, increased awareness of preventative healthcare, and rising health and wellness expenditures. The size of the world market for herbal medicines was estimated at $216.40 billion in 2023 and is expected to increase to $437 billion by 2032 from $233.08 billion in 2024. The market for herbal medicines is expected to increase from $233.08 billion to $216.40 billion by 2023.

 

FAQ Related to the Celestial Biolabs Limited

Q.1 Do Celestial Biolabs Limited is listed or not?

 Celestial Biolabs Limited is unlisted company.

Q.2 Is Celestial Biolabs Limited is profitable?

The company has shown an increasing profit and good cash flow statement position.

Q.3 when did Celestial Biolabs Limited gets delisted?

SEBI passed an order to celestial biolabs limited on 5th of October 2018.

Q.4 What is the main Work of Celestial Biolabs Limited?

Herbal and feed supplement formulations is the main work of celestial biolabs limited.

 

 

 

Annual Report

Celestial Biolabs Annual Report 2018-19

Download
Wealth Wisdom - WWIPL
Support Megha Support Neha

News Alert